Sign in →

Test Code LAMO Lamotrigine, Serum

Reporting Name

Lamotrigine, S

Useful For

Monitoring serum concentration of lamotrigine

 

Assessing compliance

 

Adjusting lamotrigine dose in patients receiving other anticonvulsant drugs which interact pharmacokinetically with lamotrigine

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Serum


Specimen Required


Collection Container/Tube:

Preferred: Red top

Acceptable: Serum gel

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Draw blood immediately before next scheduled dose.

2. For sustained-release formulations ONLY, draw blood a minimum of 12 hours after last dose.

3. Centrifuge within 2 hours of collection.

4. Aliquot serum into plastic vial.


Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 28 days
  Ambient  28 days
  Frozen  28 days

Reference Values

Patients receiving therapeutic doses usually have lamotrigine concentrations of 2.5-15.0 mcg/mL.

Day(s) and Time(s) Performed

Monday through Friday; Continuous until 2 p.m.

Saturday; Continuous until 1 p.m.

Sunday; 11 a.m.

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

80175

LOINC Code Information

Test ID Test Order Name Order LOINC Value
LAMO Lamotrigine, S 6948-4

 

Result ID Test Result Name Result LOINC Value
80999 Lamotrigine, S 6948-4

Clinical Reference

1. Johannessen SI, Battino D, Berry DJ, et al: Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit. 2003 Jun;25(3):347-363

2. Johannessen SI, Landmark CJ: Value of therapeutic drug monitoring in epilepsy. Expert Rev Neurother. 2008 Jun;8(6):929-939

3. Johannessen SI, Tomson T: Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet. 2006;45(11):1061-1075

4. Physician's Desk Reference. 71st ed. Thomson PDR; 2017

5.  Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. McGraw-Hill Book Company; 2001

6. Hiemke C, Bergemann N, Clement HW, et al: Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018 Jan;51(1-02):9-62

Method Description

Samples are diluted and extracted online extraction by high turbulence liquid chromatography, with detection by tandem mass spectrometry.(Unpublished Mayo method)

Analytic Time

Same day/1 day

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus OK
 

Method Name

Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

-Neurology Specialty Testing Client Test Request (T732)

-General Request (T239)

-Therapeutics Test Request (T831)

Secondary ID

80999